Coming off a nearly 9 percent rise in July, the GenomeWeb Index fell more than 2 percent in August, mimicking the Nasdaq Biotechnology Index, which fell 3 percent.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The GenomeWeb Index fell half a percent in June, underperforming the Dow Jones Industrial Average, but far outpacing the Nasdaq and Nasdaq Biotech Index.
The GenomeWeb Index rose 4 percent in May, in line with the Nasdaq and the Nasdaq Biotech Index, and outperforming the Dow Jones Industrial Average.
The GenomeWeb Index fell 1 percent in April, outperforming the Nasdaq, but falling significantly short of the performance of the Nasdaq Biotech Index.
The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.
The GenomeWeb Index was flat in February month over month, in line with the Dow but outperforming the Nasdaq and the Nasdaq Biotech Index.
The GenomeWeb Index fell 11 percent in January, behind the Dow and the Nasdaq, but well above the Nasdaq Biotech Index, which fell 21 percent.
There were more winners than losers in the 2015 GWDN Index, but some lost big.
Overall, the GenomeWeb Index, which tracks the share prices of 31 tools and MDx firms, jumped nearly 7 percent in the month of November.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.